Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsLevofloxacinLD 500mg PO, then 250-500mg PO Q48HAdminister Post-HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
36167-874-87624-381.1-1.544.5-98.110-21 (high flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01137
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clinical pharmacokinetics 2005; 44(3), 221-35.
  • Mochizuki M, Yuda R, Amano F et al. Comparative Studies of Dialyzability of Levofloxacin and Amlodipine Using in Vitro Dialysis System with Three Different Types of Dialyzers. Journal of Health Science 1999; 45(5), 271-5.
  • Sowinski K, Lucksiri A, Kays M, Scott M, Mueller B, Hamburger R. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. American Journal of Kidney Diseases 2003; 42(2), 342-349.
  • Tsaganos T, Kouki P, Digenis P, Giamarellou H, Giamarellos-Bourboulis E, Kanellakopoulou K. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. International journal of antimicrobial agents 2008; 32(1), 46-9.
  • Tsuruoka S, Yokota N, Hayasaka T, Saito T, Yamagata K. Pharmacokinetics of multiple-dose levofloxacin in hemodialysis patients. American journal of kidney diseases  (the official journal of the National Kidney Foundation) 2011; 58(3), 498-9.